Amgen (AMGN) Q4 FY24 earnings call

Amgen concluded 2024 with robust product sales growth and significant pipeline advancements, driven by key brands like Repatha, EVENITY, and TEZSPIRE, alongside a growing biosimilar portfolio. The company is strategically investing in its late-stage pipeline, particularly MariTide and olpasiran, while navigating pricing pressures and upcoming patent expirations. Management remains focused on global expansion and operational efficiency to sustain long-term growth and innovation.